FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1972268082> ?p ?o ?g. }

• W1972268082 endingPage "3082" @default.
• W1972268082 startingPage "3076" @default.
• W1972268082 abstract "Purpose Multiple investigational drugs are currently explored in cancer patient populations defined by specific biomarkers. This demands a new process of patient selection for clinical trials. Patients and methods Starting January 1, 2012, preemptive biomarker profiling was offered at the West German Cancer Center to all patients with advanced non-small-cell lung (NSCLC) or colorectal cancer (CRC), who met generic study inclusion criteria. Tumour specimens were subjected to prespecified profiling algorithms to detect ‘actionable biomarkers’ by amplicon sequencing, in situ hybridisation and immunohistochemistry. The clinical course was closely monitored to offer trial participation whenever applicable. Results Within 12 months, 267 patients (188 NSCLC, 79 CRC) were profiled. Estimated additional cost for biomarker profiling was 219615.51 EUR excluding histopathology workup and administration. The most prevalent biomarkers in pulmonary adenocarcinoma were KRAS mutations (29%), loss of PTEN expression (18%), EGFR mutations (9%), HER2 amplification (5%) and BRAF mutations (3%), while the prevalence of ALK translocations and PIK3CA mutations was extremely low. In pulmonary squamous cell carcinoma FGFR1 amplifications were found in 15%, PTEN expression was lost in 20% and DDR2 was mutated in a single case. KRAS mutations (41%) predominated in CRC, followed by loss of PTEN expression (16%), PIK3CA (5%) and BRAF (5%) mutations. So far 13 patients (5%) have entered biomarker-stratified clinical trials. Therapeutic decisions for approved drugs were guided in another 45 patients (17%). Conclusion Preemptive biomarker profiling can be implemented into the diagnostic algorithm of a large Comprehensive Cancer Center. Substantial investments in diagnostics and administration are required." @default.
• W1972268082 created "2016-06-24" @default.
• W1972268082 creator A5001668405 @default.
• W1972268082 creator A5005413568 @default.
• W1972268082 creator A5007861447 @default.
• W1972268082 creator A5014781639 @default.
• W1972268082 creator A5023684301 @default.
• W1972268082 creator A5023794918 @default.
• W1972268082 creator A5026512515 @default.
• W1972268082 creator A5030508124 @default.
• W1972268082 creator A5031540987 @default.
• W1972268082 creator A5034451063 @default.
• W1972268082 creator A5035412618 @default.
• W1972268082 creator A5036507802 @default.
• W1972268082 creator A5040808094 @default.
• W1972268082 creator A5043479866 @default.
• W1972268082 creator A5045084441 @default.
• W1972268082 creator A5046824768 @default.
• W1972268082 creator A5046955385 @default.
• W1972268082 creator A5047006205 @default.
• W1972268082 creator A5052897797 @default.
• W1972268082 creator A5061566639 @default.
• W1972268082 creator A5061830141 @default.
• W1972268082 creator A5069288405 @default.
• W1972268082 creator A5071485077 @default.
• W1972268082 creator A5071766547 @default.
• W1972268082 creator A5073234708 @default.
• W1972268082 creator A5079195039 @default.
• W1972268082 creator A5080104306 @default.
• W1972268082 creator A5082059315 @default.
• W1972268082 creator A5083358107 @default.
• W1972268082 creator A5084845830 @default.
• W1972268082 date "2013-10-01" @default.
• W1972268082 modified "2023-10-18" @default.
• W1972268082 title "Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center" @default.
• W1972268082 cites W2027052672 @default.
• W1972268082 cites W2028835984 @default.
• W1972268082 cites W2038624343 @default.
• W1972268082 cites W2047004048 @default.
• W1972268082 cites W2059336669 @default.
• W1972268082 cites W2088905520 @default.
• W1972268082 cites W2096283457 @default.
• W1972268082 cites W2103146352 @default.
• W1972268082 cites W2107633226 @default.
• W1972268082 cites W2133540186 @default.
• W1972268082 cites W2144918562 @default.
• W1972268082 cites W2150575159 @default.
• W1972268082 cites W2150625137 @default.
• W1972268082 cites W2159060826 @default.
• W1972268082 cites W2163798887 @default.
• W1972268082 cites W2167014571 @default.
• W1972268082 cites W2275877493 @default.
• W1972268082 cites W2288763477 @default.
• W1972268082 doi "https://doi.org/10.1016/j.ejca.2013.06.014" @default.
• W1972268082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23876834" @default.
• W1972268082 hasPublicationYear "2013" @default.
• W1972268082 type Work @default.
• W1972268082 sameAs 1972268082 @default.
• W1972268082 citedByCount "25" @default.
• W1972268082 countsByYear W19722680822014 @default.
• W1972268082 countsByYear W19722680822015 @default.
• W1972268082 countsByYear W19722680822016 @default.
• W1972268082 countsByYear W19722680822017 @default.
• W1972268082 countsByYear W19722680822018 @default.
• W1972268082 countsByYear W19722680822019 @default.
• W1972268082 countsByYear W19722680822020 @default.
• W1972268082 countsByYear W19722680822021 @default.
• W1972268082 crossrefType "journal-article" @default.
• W1972268082 hasAuthorship W1972268082A5001668405 @default.
• W1972268082 hasAuthorship W1972268082A5005413568 @default.
• W1972268082 hasAuthorship W1972268082A5007861447 @default.
• W1972268082 hasAuthorship W1972268082A5014781639 @default.
• W1972268082 hasAuthorship W1972268082A5023684301 @default.
• W1972268082 hasAuthorship W1972268082A5023794918 @default.
• W1972268082 hasAuthorship W1972268082A5026512515 @default.
• W1972268082 hasAuthorship W1972268082A5030508124 @default.
• W1972268082 hasAuthorship W1972268082A5031540987 @default.
• W1972268082 hasAuthorship W1972268082A5034451063 @default.
• W1972268082 hasAuthorship W1972268082A5035412618 @default.
• W1972268082 hasAuthorship W1972268082A5036507802 @default.
• W1972268082 hasAuthorship W1972268082A5040808094 @default.
• W1972268082 hasAuthorship W1972268082A5043479866 @default.
• W1972268082 hasAuthorship W1972268082A5045084441 @default.
• W1972268082 hasAuthorship W1972268082A5046824768 @default.
• W1972268082 hasAuthorship W1972268082A5046955385 @default.
• W1972268082 hasAuthorship W1972268082A5047006205 @default.
• W1972268082 hasAuthorship W1972268082A5052897797 @default.
• W1972268082 hasAuthorship W1972268082A5061566639 @default.
• W1972268082 hasAuthorship W1972268082A5061830141 @default.
• W1972268082 hasAuthorship W1972268082A5069288405 @default.
• W1972268082 hasAuthorship W1972268082A5071485077 @default.
• W1972268082 hasAuthorship W1972268082A5071766547 @default.
• W1972268082 hasAuthorship W1972268082A5073234708 @default.
• W1972268082 hasAuthorship W1972268082A5079195039 @default.
• W1972268082 hasAuthorship W1972268082A5080104306 @default.
• W1972268082 hasAuthorship W1972268082A5082059315 @default.
• W1972268082 hasAuthorship W1972268082A5083358107 @default.
• W1972268082 hasAuthorship W1972268082A5084845830 @default.

• next